Britannia Life Sciences Inc (BLAB) AI Stock Analysis

• Market Cap: C$12.98M
• Dividend Yield: N/A
• Average Volume (3M): 73.07K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.14
• Revenue Growth: -3.93%
• EPS Growth: -575.24%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 162,254,330
• 10 Day Avg. Volume: 81,691
• 30 Day Avg. Volume: 73,070
• PEG Ratio: -0.81
• Price to Book (P/B): 1.93
• Price to Sales (P/S): 32.95
• P/FCF Ratio: -4.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.08 ▼(-12.22% Downside)

The overall stock score is primarily influenced by the company's volatile financial performance and weak valuation. Technical analysis provides a slightly more positive outlook, but the lack of profitability and financial stability are significant concerns.

Positive Factors

Diversified revenue model

Multiple durable revenue streams—product sales, licensing, pharma collaborations, grants and partnerships—reduce single‑market dependency. This mix supports cash generation variety, cross‑selling opportunities, and long‑run resilience as the company scales its diagnostics and therapeutic efforts.

Strong top‑line growth

Sustained, high revenue growth indicates accelerating product adoption or successful commercial partnerships, which can drive economies of scale. If maintained, this trend enables higher R&D reinvestment and market penetration, underpinning durable expansion even as margins are addressed.

Improving leverage and positive ROE

Improving leverage and a positive trailing ROE reflect better capital structure management and some ability to generate returns for shareholders. These durable improvements increase financial flexibility for investments, partnerships, or R&D without excessive financing strain.

Negative Factors

Persistent unprofitability

Despite high gross margins, the company posts negative net margins and volatile operating profitability. Long‑term value creation depends on translating revenue into consistent operating profits; without margin stabilization, sustained free cash generation and reinvestment capacity remain at risk.

Negative operating cash flow

Negative operating cash flow signals the core business is not yet consistently converting revenue into cash, implying reliance on non‑operational sources or financing. Over months, this undermines funding for R&D, commercialization, and reduces resilience to funding shocks unless operating cash improves.

Low equity ratio and historical leverage

A low equity ratio and history of high leverage reduce the balance sheet buffer against shocks and limit capacity for large investments or M&A. Structurally, this increases refinancing and solvency risk over the medium term and can constrain strategic options if cash generation falters.

Britannia Life Sciences Inc Business Overview & Revenue Model

Company Description

Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.

How the Company Makes Money

Britannia Life Sciences Inc generates revenue through multiple streams, primarily from the sale of proprietary diagnostic products, licensing agreements for its patented technologies, and collaborations with pharmaceutical companies for drug development. The company also earns income from research grants and funding, as well as strategic partnerships that enhance its product offerings and market reach. Significant collaborations with health institutions and industry partners further bolster its revenue by providing access to broader markets and shared resources.

Britannia Life Sciences Inc Financial Statement Overview

Summary

Britannia Life Sciences Inc faces significant financial challenges, with declining revenues and profitability issues. The balance sheet shows high leverage, although recent improvements in equity and net income are positive signs. Cash flow remains a concern, with negative operating cash flow indicating potential liquidity constraints. Overall, the company needs to address these issues to stabilize and improve its financial health.

Income Statement

The income statement reveals significant challenges, with negative revenue growth and fluctuating profit margins. The TTM data shows a drastic revenue decline, and net profit margins are negative, indicating profitability issues. However, there is a positive net income in the latest TTM, which is a slight improvement.

Balance Sheet

The balance sheet shows a mixed picture with a manageable debt-to-equity ratio in the TTM, but historical data indicates high leverage and negative equity in some periods. The return on equity has improved recently, but overall stability remains a concern due to fluctuating equity levels.

Cash Flow

Cash flow analysis highlights negative operating cash flow and free cash flow in the TTM, with some improvement in free cash flow growth. The ratios indicate cash flow challenges relative to net income, suggesting potential liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-2.97M	369.28K	7.57M	6.40M	7.30M	1.42M
Gross Profit	-2.33M	27.33K	4.85M	4.64M	5.26M	1.17M
EBITDA	-4.56M	-4.39M	-1.90M	6.95M	-10.77M	-1.62M
Net Income	8.22M	7.39M	-4.77M	5.08M	-15.46M	-157.16K
Balance Sheet
Total Assets	10.31M	11.61M	22.26M	23.55M	21.09M	21.45M
Cash, Cash Equivalents and Short-Term Investments	861.63K	7.85M	1.32M	2.60M	1.63M	828.32K
Total Debt	2.41M	1.86M	7.29M	8.41M	5.19M	10.55M
Total Liabilities	5.26M	5.31M	15.59M	12.49M	15.61M	18.79M
Stockholders Equity	5.05M	6.30M	2.44M	7.02M	1.35M	-202.32K
Cash Flow
Free Cash Flow	-4.50M	-2.62M	1.75M	874.41K	2.71M	-543.49K
Operating Cash Flow	-4.40M	-2.62M	2.09M	1.22M	2.80M	-586.58K
Investing Cash Flow	6.20M	11.27M	-1.44M	-3.32M	653.95K	-4.91M
Financing Cash Flow	-1.91M	-2.17M	-1.97M	2.95M	-2.58M	6.20M

Britannia Life Sciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.09, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.97 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BLAB.

Britannia Life Sciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GLOW	49 Neutral	C$10.87M	-4.41	-153.85%	―	239.98%	39.01%
BLAB	47 Neutral	C$12.98M	-1.60	―	―	-3.93%	-575.24%
HEM	41 Neutral	C$16.96M	-3.09	―	―	―	-24.89%

Britannia Life Sciences Inc Corporate Events

Britannia Life Sciences Enters $11.3 Million Share Exchange Agreement

Britannia Life Sciences Inc. has entered into an $11.3 million share exchange agreement with McEwen Inc. and Britannia Mining Solutions Inc., marking a significant step in its strategy to unlock value from its portfolio. This transaction enhances Britannia’s position to invest in other cash-generative businesses, potentially increasing returns for shareholders. Additionally, Britannia is extending the closing of its debenture offering to November 30, 2025, as it continues to engage with potential investors.